Chong Kun Dang Pharmaceutical

This phase 3 trial tests whether a new combination drug (CKD-202A, containing sacubitril and valsartan) works better than valsartan alone for lowering blood pressure in people with essential hypertension. About 324 adults aged 19 and older will take part. The study is currently r…

This early-stage trial tests a new biosimilar drug called CKD-704, which is designed to work like the approved psoriasis treatment Skyrizi. About 213 healthy adults will receive a single dose of either CKD-704, EU-approved Skyrizi, or US-licensed Skyrizi to compare how the drugs …

This study tests a new drug called CKD-703 for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. The drug is designed to seek out and attack cancer cells that have a specific marker (c-Met) while…

This early-stage study tests a new drug called CKD-512, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 60 participa…

This early-stage study tests a new drug called CKD-706 in healthy adults aged 18 to 55. It compares how the body processes CKD-706 versus two versions of the approved drug Dupixent (one made in the US, one in the EU). The goal is to check safety, drug levels, and immune response,…